Please ensure Javascript is enabled for purposes of website accessibility

Why Intersect ENT Shot 12% Higher on Friday

By Eric Volkman – Aug 6, 2021 at 4:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's official: A big peer is buying out the specialty medical device maker.

What happened

Intersect ENT (XENT), a medical device maker specializing in technology for the ear, nose, and throat segment, had a memorable Friday. On the same day it delivered its latest quarterly results, a peer announced it was acquiring the company.

So what

That peer is medical device giant Medtronic (MDT 0.13%), which has signed a definitive agreement to purchase Intersect ENT for $28.25 per share in a deal with an enterprise value estimated at around $1.1 billion. The news comes less than a month after it was revealed that Medtronic had made a formal buyout offer.

That per-share price is 15% higher than Intersect ENT's closing level on Thursday, hence Friday's price leap. 

The deal is subject to approval by Intersect ENT shareholders. Given the stock price premium and the company's absorption into a device segment leader, it's hard to imagine there will be much objection. Medtronic said that if approved, the acquisition should close by the end of its current fiscal year.

Piggy bank with stethoscope.

Image source: Getty Images.

Meanwhile, for its Q2, Intersect ENT's revenue came in at $27.3 million, which was 180% higher year over year. The non-GAAP (adjusted) net loss was $16.6 million ($0.49 per share), narrower than the $21 million the company lost in the year-ago quarter.

On average, analysts tracking the stock were modeling a top-line figure of just over $28 million, and an adjusted net loss of $0.43 per share.

Now what

While there have been higher premiums in the recent history of healthcare industry buyouts, this one is fairly generous given Intersect ENT's habitual bottom-line losses. Investors should unhesitatingly vote in favor of this deal.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intersect ENT Stock Quote
Intersect ENT
Medtronic Stock Quote
$79.12 (0.13%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.